Medtronic plc (MDT)
Health Care10 articles
Price chart
Why is MDT moving today?
-0.7%MDT is -0.7% today, inside the ordinary range for a session (under 3%). No stories about it reached the feed in the last 24 hours.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of 7 hours ago
Medtronic plc (MDT) overview
Medtronic is one of the world’s largest medical-device makers.
MDT is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
Medtronic plc trades on the NYSE under the ticker symbol MDT. The most recent market data puts the share price at about $94.75. That is down 0.73% on the session. At that price the company is worth roughly $121.20B.
Over the past 52 weeks, MDT has traded between $73.31 and $106.33. Shares change hands at a trailing price-to-earnings (P/E) ratio of about 23.3. The P/E ratio sets the share price against a year of earnings. A higher number means the market is paying more for each dollar the company earns. MDT also pays a dividend. It yields around 3.02% at the current price.
Key statistics
Source: Yahoo Finance - quote as of 7 hours ago
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch MDT
MDT is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each MDT story as it breaks, and tags it bullish, bearish or neutral.
Size matters here as well. The S&P 500 is weighted by market value. MDT is large enough that its own share price nudges the whole index. So it is worth watching even for investors who only hold index funds.
What moves MDT
- Earnings. MDT reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from MDT.
- Sector news. Health Care stocks often move together, so a rival's news can move MDT too.
- Index weight. MDT is big enough to move the S&P 500 on its own.
Market Mood
Latest MDT news
Johnson & Johnson's Competitive Edge Over Medtronic in History
The article discusses historical performance trends, indicating that Johnson & Johnson (JNJ) has historically outperformed Medtronic (MDT). However, the analysis suggests considering Medtronic for long-term potential. This performance comparison includes various market factors affecting both companies. Overall, investors might evaluate Medtronic's future alongside its historical context when making investment decisions.
Read More: Johnson & Johnson's Competitive Edge Over Medtronic in History
MiniMed Registration for Medtronic (MDT) Exchange Offer Filed
Medtronic (MDT) has filed for registration related to an exchange offer for its MiniMed division. This event signifies a strategic move by Medtronic as it looks to restructure or refinance its assets. The filing could influence investor sentiments regarding the company's future direction and financial stability. Monitoring this exchange offer is crucial for ordinary investors as it may impact the company's stock performance.
Read More: MiniMed Registration for Medtronic (MDT) Exchange Offer Filed
GE HealthCare (GEHC) and Medtronic (MDT) Options Bets Recommend Decline
Analysts recommend options bets against GE HealthCare (GEHC) and Medtronic (MDT) due to an oversaturation of bullish positions. This shift suggests a potential reversal in the sentiment surrounding these stocks, indicating that a decline could be imminent. Investors have already made numerous bets that these stocks would rise, which may prompt a market correction. This recommendation matters for investors as it highlights a shift in market sentiment within the crowded healthcare sector.
Read More: GE HealthCare (GEHC) and Medtronic (MDT) Options Bets Recommend Decline
Medtronic (MDT) Reports 78% Revenue Growth in Q4 2026 Earnings
Medtronic plc (NYSE: MDT) achieved its highest annual revenue growth in a decade, reporting a global revenue increase of 78%, with 124% growth in the U.S. for its Cardiac Ablation Solutions. The company is focusing on innovations and acquisitions to support potential growth across its portfolio. In contrast, Tenet Healthcare Corporation (NYSE: THC) saw adjusted diluted EPS rise 52.2% year over year to $6.12, with net operating revenue climbing 6.8% to $5.63 billion. As both companies demonstrate strong performance, this information helps investors evaluate which stock might better suit their growth strategy.
Read More: Medtronic (MDT) Reports 78% Revenue Growth in Q4 2026 Earnings
Medtronic (MDT) Reports 9.9% Q4 Revenue Growth, UBS Upgrades Stock
Medtronic (NYSE: MDT) announced Q4 revenue of $9.8 billion, reflecting a 9.9% increase, while fiscal 2026 revenue reached $36.4 billion, up 8.4%. The company achieved its highest annual revenue growth in 10 years, driven by significant performance in its cardiac segment, with Cardiac Ablation Solutions revenue increasing by 78%. UBS upgraded Medtronic from Neutral to Buy, citing signs of a turnaround after several years of underperformance. This information is important for investors as it indicates potential renewed growth and improved prospects for Medtronic, factoring into decisions on stock valuation and investment strategies.
Read More: Medtronic (MDT) Reports 9.9% Q4 Revenue Growth, UBS Upgrades Stock
Medtronic Faces $88 Million Verdict in Hernia Mesh Trial
Medtronic has been ordered to pay $88 million in a verdict related to a hernia mesh trial. The jury found that the company was liable for damages due to complications linked to its product. This verdict comes amidst ongoing litigation concerning the safety and effectiveness of Medtronic's hernia mesh devices. Such legal outcomes can impact Medtronic's (MDT) reputation and financial performance, influencing investor sentiment and market confidence.
Read More: Medtronic Faces $88 Million Verdict in Hernia Mesh Trial
Medtronic (MDT) Reports Highest Annual Revenue Growth in Decade
Medtronic (MDT) reported its highest annual revenue growth in a decade, signaling a potential recovery after years of profitability challenges. The company boasts a 49-year dividend growth streak and currently offers a dividend yield of 3.5%. Conversely, Realty Income (O), a REIT, has maintained a 5.2% dividend yield, increasing its dividend for 31 consecutive years, making it attractive amid market volatility. Investor interest in reliable dividend stocks remains strong as corrections loom in the broader market.
Read More: Medtronic (MDT) Reports Highest Annual Revenue Growth in Decade
Medtronic (MDT) Tariff Impact Reduces Estimates to $250 Million
Medtronic plc (MDT) CEO Geoffrey Martha announced on June 8 that the company expects a tariff impact of $250 million for fiscal 2027, down from a previous estimate of $300 million. This figure includes $75 million expected in the first quarter. The reduction is due to supply chain adjustments, although Martha indicated that future tariff threats could alter these forecasts. Medtronic allocates $5 billion to $6 billion annually for innovation and reported a 78% revenue increase in cardiac ablation amidst ongoing cost pressures.
Read More: Medtronic (MDT) Tariff Impact Reduces Estimates to $250 Million
Medtronic (MDT) Reports Strong Q4 with $36 Billion Revenue Growth
Medtronic (MDT) recorded fiscal 2026 revenue of $36.36 billion, an 8.43% increase year-over-year. The company raised its quarterly dividend to $0.72, yielding approximately 3.52%, marking 49 consecutive years of increases. Trading at 14 times forward earnings, MDT demonstrates defensive value due to its non-discretionary medical procedures and a beta of 0.597. Key risks include a $185 million tariff and 230-basis-point margin compression, but underlying demographics may support long-term growth.
Read More: Medtronic (MDT) Reports Strong Q4 with $36 Billion Revenue Growth
Medtronic (MDT) Gains FDA Approval for New Robotic Surgery Platform
Medtronic (MDT) received FDA approval for its Hugo robotic-assisted surgery platform in December 2025, allowing it to perform urologic procedures. The first successful use occurred at Cleveland Clinic shortly after. This market is projected to grow from $13.8 billion in 2022 to $63.7 billion by 2035, yet Medtronic faces significant competition from Intuitive Surgical, which dominates the market with over 11,395 da Vinci systems installed globally. With a recent application for broader procedure approvals, Medtronic aims to expand its market presence but may have an uphill battle against a well-entrenched competitor.
Read More: Medtronic (MDT) Gains FDA Approval for New Robotic Surgery PlatformMore Health Care stocks
Frequently asked questions
Is Medtronic plc in the S&P 500?
Yes. Medtronic plc trades as MDT and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is MDT in?
MDT sits in the Health Care sector of the S&P 500.
Where can I find the latest MDT news?
Right here. This page collects recent MDT news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is Medtronic plc's stock price?
MDT last traded at about $94.75. Prices move all through the session, so this is the latest quote rather than a live one.
What is Medtronic plc's market cap?
MDT is worth roughly $121.20B. Market cap is the share price times the number of shares outstanding.
What is MDT's P/E ratio?
MDT trades at a trailing P/E ratio of about 23.3. The ratio compares the share price with earnings per share over the past year.